Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 0.75 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.75 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.75 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.75 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386401 | 1.00 | F11 (0.75) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2330542 | 0.90 | F11 (0.60) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2328198 | 0.87 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2331259 | 0.87 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2333539 | 0.86 | F11 (0.75) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2333543 | 0.86 | F11 (0.75) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2325770 | 0.85 | F11 (0.80) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2324123 | 0.85 | F11 (0.80) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2328259 | 0.85 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 | |
| SCHEMBL2328257 | 0.85 | F11 (1.00) | F11KLKB1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4834663-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1773775-B1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-08-17 | — | — | EP | claimed |
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | claimed |
| JP-2008502692-A | — | — | 2008-01-31 | — | — | JP | claimed |
| EP-1773775-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-12 | — | — | US | claimed |
| WO-2005123680-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | claimed |
| EP-1773775-B1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | F12, F11, F2 | F11 2/4885KLKB1 10/4885PRSS1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.